|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PYY |
Gene summary for PYY |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PYY | Gene ID | 5697 |
| Gene name | peptide YY | |
| Gene Alias | PYY-I | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0002065 | UniProtAcc | P10082 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5697 | PYY | HTA11_411_2000001011 | Human | Colorectum | SER | 1.82e-07 | 3.15e+00 | -0.2602 |
| 5697 | PYY | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.34e-02 | 1.06e+00 | -0.1706 |
| 5697 | PYY | AEH-subject5 | Human | Endometrium | AEH | 5.49e-12 | 4.50e-01 | -0.2953 |
| 5697 | PYY | EEC-subject1 | Human | Endometrium | EEC | 1.64e-04 | 1.98e-01 | -0.2682 |
| 5697 | PYY | EEC-subject4 | Human | Endometrium | EEC | 1.45e-11 | 4.21e-01 | -0.2571 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PYY | SNV | Missense_Mutation | novel | c.220N>G | p.Leu74Val | p.L74V | P10082 | protein_coding | tolerated(0.97) | benign(0.001) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PYY | SNV | Missense_Mutation | c.202G>C | p.Asp68His | p.D68H | P10082 | protein_coding | deleterious(0.01) | possibly_damaging(0.519) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| PYY | SNV | Missense_Mutation | c.230N>T | p.Thr77Met | p.T77M | P10082 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| PYY | SNV | Missense_Mutation | rs754534017 | c.10N>A | p.Val4Met | p.V4M | P10082 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| PYY | SNV | Missense_Mutation | c.182G>A | p.Arg61Gln | p.R61Q | P10082 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PYY | SNV | Missense_Mutation | rs559556349 | c.14G>A | p.Arg5His | p.R5H | P10082 | protein_coding | tolerated(0.5) | benign(0.028) | TCGA-AP-A0LE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PYY | SNV | Missense_Mutation | novel | c.276N>T | p.Glu92Asp | p.E92D | P10082 | protein_coding | tolerated(0.99) | benign(0.031) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PYY | SNV | Missense_Mutation | novel | c.86N>G | p.Tyr29Cys | p.Y29C | P10082 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| PYY | SNV | Missense_Mutation | novel | c.241N>A | p.Asp81Asn | p.D81N | P10082 | protein_coding | tolerated(0.09) | possibly_damaging(0.802) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PYY | SNV | Missense_Mutation | rs748873545 | c.182N>T | p.Arg61Leu | p.R61L | P10082 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-98-A53A-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5697 | PYY | DRUGGABLE GENOME, HORMONE ACTIVITY | Peptide YY 3-36 | |||
| 5697 | PYY | DRUGGABLE GENOME, HORMONE ACTIVITY | TYROSINE KINASE INHIBITOR | 10970776 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |